

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-38 (Cancelled).

39 (Currently Amended). A method for treatment of a psychiatric disorder, disease or condition selected from the group consisting of post-traumatic stress disorder (PTSD), depression, bipolar disorder and schizophrenia~~and-related disorders~~, which comprises administering to an individual in need of such a treatment an effective amount of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

40 (Currently Amended). A method for treatment of a psychiatric disorder, disease or condition selected from the group consisting of post-traumatic stress disorder (PTSD), depression, bipolar disorder and schizophrenia~~and-related disorders~~, which comprises immunizing an individual in need of such a treatment with a therapeutically effective amount of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

41 (Previously Presented). The method according to claim 39, wherein said agent is Copolymer 1.

42 (Previously Presented). The method according to claim 39, wherein said agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.

43 (Previously Presented). The method according to claim 39, wherein said agent is T cells which have been activated by Copolymer 1.

44 (Cancelled).

45 (Withdrawn). The method according to claim 39, wherein said psychiatric disorder, disease or condition is post-traumatic stress disorder (PTSD).

46 (Withdrawn). The method according to claim 39, wherein said psychiatric disorder, disease or condition is post-traumatic stress disorder (PTSD) and said agent is Copolymer 1.

47 (Withdrawn). The method according to claim 39, wherein said psychiatric disorder, disease or condition is selected from the group consisting of depression and bipolar disorders.

48 (Previously Presented). The method according to claim 39, wherein said psychiatric disorder, disease or condition is schizophrenia and said agent is Copolymer 1.

49-51 (Cancelled).

52 (Previously Presented). The method according to claim 41, wherein the Copolymer 1 is administered in the form of a vaccine.

53 (Previously Presented). The method according to claim 52, wherein said vaccine comprises Copolymer 1 without an adjuvant.

54 (Previously Presented). The method according to claim 52, wherein said vaccine comprises Copolymer 1 emulsified in an adjuvant suitable for human clinical use.

55 (Previously Presented). The method according to claim 54, wherein said adjuvant is aluminum hydroxide, aluminum hydroxide gel or aluminum hydroxyphosphate.